CDC Reports on Influenza Activity in the United States During the 2017–18 Season and Composition of the 2018–19 Influenza Vaccine

PUBLISHED: Jun 11, 2018
Relevant to: All Healthcare Organizations

According to the U.S Centers for Disease Control and Prevention (CDC), the United States 2017–18 influenza season (October 1, 2017–May 19, 2018) was a high severity season with high levels of outpatient clinic and emergency department visits for influenza-like illness (ILI), high influenza-related hospitalization rates, and elevated and geographically widespread influenza activity across the country for an extended period. Nationally, ILI activity began increasing in November, reaching an extended period of high activity during January–February, and remaining elevated through March. Influenza A(H3N2) viruses predominated through February and were predominant overall for the season; influenza B viruses predominated from March onward.

While the CDC and partners are working to improve existing flu countermeasures, increases in flu vaccine uptake and the appropriate use of antiviral drugs for treatment could further reduce the burden of influenza in the United States. Studies are underway to better understand the reasons for this high severity. In addition, a high number of influenza-associated pediatric deaths were reported this season.

The Food and Drug Administration’s Vaccines and Related Biologic Products Advisory Committee recommended that the 2018–19 trivalent vaccine to be used in the United States contain an A/Michigan/45/2015 A(H1N1)pdm09-like virus, an A/Singapore/INFIMH-16–0019/2016 A(H3N2)-like virus, and a B/Colorado/06/2017-like (B/Victoria lineage) virus. The quadrivalent vaccine recommendation included the trivalent vaccine viruses as well as a B/Phuket/3073/2013-like (B/Yamagata lineage) virus. The B component recommendation represents a change in the influenza B/Victoria lineage component recommended for the 2017–2018 Northern Hemisphere and 2018 Southern Hemisphere influenza vaccines. The B component change was made because of the increasing global circulation of an antigenically drifted B/Victoria lineage virus (V1A.1).

The A(H3N2) recommendation represents an update to the 2017–2018 Northern Hemisphere vaccines but is the same A(H3N2) virus recommended for the 2018 Southern Hemisphere vaccine. The decision to update the A(H3N2) component was not made to address antigenic drift, but rather because the egg-propagated A/Singapore vaccine virus is antigenically more similar to circulating viruses than the egg-propagated A/Hong Kong vaccine virus recommended for the Northern Hemisphere 2017–2018 vaccine. Vaccine recommendations were based on factors including global influenza virologic and epidemiologic surveillance, genetic characterization, antigenic characterization, and the candidate vaccine viruses that are available for production.

Follow the link below for additional information.

Want to read the full alert and receive alert emails?

Browse Additional Alerts